{"id":6279,"date":"2019-10-29T12:23:19","date_gmt":"2019-10-29T06:53:19","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=6279"},"modified":"2021-07-24T12:57:36","modified_gmt":"2021-07-24T07:27:36","slug":"recent-pharma-happenings-for-az-allergan-gilead-glympse-bio","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-az-allergan-gilead-glympse-bio","title":{"rendered":"AZ announces positive results for durvalumab and tremelimumab; FDA nods to extend LILETTA\u2019s use to prevent pregnancy; Gilead, Glympse Bio teams up to advance NASH clinical development"},"content":{"rendered":"\n

AstraZeneca recently has announced the results of\nthe clinical trials POSEIDON which included the study of a combination of drugs\nImfinzi (durvalumab) and tremelimumab with chemotherapy in lung cancer. <\/strong><\/p>\n\n\n\n

Imfinzi is a human monoclonal antibody which blocks the interaction of PD-L1 with PD-1 by binding itself with the former. FDA approved the use of the drug in early for the treatment of unresectable stage III non-small cell lung cancer<\/a> (NSCLC) and locally advanced or metastatic urothelial carcinoma. <\/p>\n\n\n\n

Tremelimumab, on the other hand, is a fully human monoclonal antibody which works against Cytotoxic T-cell lymphocyte-associated protein 4 (CTLA-4) and boosts the action of the T-lymphocytes and immune response against cancer. The drug has been under investigation for NSCLC<\/a>, locally-advanced or metastatic urothelial carcinoma<\/a>, head and neck cancer, liver cancer and blood cancers.<\/p>\n\n\n\n

POSEIDON trial was able to show a significant improvement\nin the NSCLC patients who were subjected to a combination of Imfinzi and a\nbroad choice of five standard-of-care platinum-based chemotherapy options as\ncompared to the patients who were administered with chemotherapy alone. The combination\ntherapy saw no compromise with the safety and tolerability and was in line with\nthe <\/p>\n\n\n\n

 According to the American Cancer Society\u2019s\nestimates, about 228,150 new cases of lung cancer are expected to get reported\nby the end of the year 2019. Moreover, approximately 142,670 deaths will be\nfrom lung cancer. <\/p>\n\n\n\n

As per the analysis by DelevInsight, the non-small\ncell lung cancer treatment landscape, for the past two decades, revolved around\nchemotherapy regimens. Chemotherapy often consists of a combination of drugs,\nsuch as cisplatin (Platinol) or carboplatin (Paraplatin) plus docetaxel\n(Taxotere), gemcitabine (Gemzar), paclitaxel (Taxol and others), vinorelbine\n(Navelbine and others), or pemetrexed (Alimta). Conventional cancer treatments,\nincluding surgical resection, chemotherapy, and\/or radiotherapy, have shown\nmodest progress in NSCLC survival over the past two decades.<\/p>\n\n\n\n

Recent years experienced the ingression of immune-checkpoint inhibitors into non-small cell lung cancer therapeutics market. Besides Imfinzi (durvalumab), Pembrolizumab (Keytruda), Nivolumab (Opdivo), and Atezolizumab (Tecentriq) are the other immune-checkpoint inhibitors in first-line and second-line NSCLC treatment.<\/p>\n\n\n\n

Gilead Sciences and Glympse Bio have announced\na strategic collaboration aiming to use Biomarker Technology in Nonalcoholic\nsteatohepatitis (NASH) clinical development. <\/strong><\/p>\n\n\n\n

Glympse Bio\u2019s synthetic biomarkers are with identifying the stage and progression of the disease helping in early detection. They will be utilized to determine the clinical trial participants\u2019 stage of the disease and response to the NASH <\/a>clinical trial. The company combines its biomarkers with machine intelligence to identify the stage and monitor the progression of complex diseases such as cancer, fibrosis, inflammation, and infections. <\/p>\n\n\n\n

The news of entering into strategic partnership came days after it announced the not so positive results in the mid-stage trials of its JAK-inhibitor filgotinib for Lupus<\/a> and Sjogren’s syndrome.  <\/p>\n\n\n\n

Filgotinib has been approved for the treatment of moderate-to-severe rheumatoid arthritis. Moreover, Filgotinib is also under trials for diseases including   Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, Sj\u00f6gren’s syndrome, cutaneous lupus<\/a>, and uveitis. <\/p>\n\n\n\n

More than one million people in the United States have been diagnosed with Sj\u00f6gren’s syndrome out of which around 90% of the affected patient pool comprises of women. <\/p>\n\n\n\n

Sj\u00f6gren’s syndrome prevalence, published in a journal of NCBI, is 0.2%, with an incidence of 4 cases per 100,000 per year. Moreover, Sjogren’s is 20 times more common in females than in males. About half of the patients also have rheumatoid arthritis or other connective tissue diseases, such as lupus.<\/p>\n\n\n\n

The Sj\u00f6gren\u2019s syndrome therapeutics market size, as analyzed by DelveInsight, is mainly accounted by symptomatic treatment including local therapies (pilocarpine, cevimeline, topical fluoride, topical cyclosporine, autologous serum eye drops, and others), systemic therapies (corticosteroids, hydroxychloroquine<\/a>) and immunosuppressants (Methotrexate (MTX), Cyclosporine A, Azathioprine, Leflunomide, and Mycophenolic acid) are commonly used interventions. Moreover, biological therapy with Rituximab is in extensive use for the US market.<\/p>\n\n\n\n

The US FDA has extended the use of LILETTA (levonorgestrel-releasing\nintrauterine system) 52 mg for up to six years making it the longest approved\nhormonal IUD in the US.  <\/strong><\/p>\n\n\n\n

Liletta, developed by Medicines360 in partnership with Allergan, a\nnon-profit organization, is a hormone-releasing system placed in the\nuterus of women which offers long-term and a reliable option to prevent pregnancy\nand is a reversible option. <\/p>\n\n\n\n

Many American women have been using Liletta as a safe and viable measure\nto avoid unwanted pregnancies. The extension of the use of the IUD for up to\nsix years came after the data based on the ongoing ACCESS IUS trials in women of age range between\n16 to 45. <\/p>\n\n\n\n

Liletta first received the FDA approval in the year 2015, and since then the companies have continued to invest more time and research in the product. The continuous efforts have resulted in the extension of the use for up to six years. <\/p>\n","protected":false},"excerpt":{"rendered":"

AstraZeneca recently has announced the results of the clinical trials POSEIDON which included the study of a combination of drugs Imfinzi (durvalumab) and tremelimumab with chemotherapy in lung cancer. Imfinzi is a human monoclonal antibody which blocks the interaction of PD-L1 with PD-1 by binding itself with the former. FDA approved the use of the […]<\/p>\n","protected":false},"author":1,"featured_media":6280,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[1271,704,794,349,1469,639],"industry":[17225],"therapeutic_areas":[17239,17228,17411],"class_list":["post-6279","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-delveinsight-pharma-news","tag-fda","tag-gilead","tag-latest-pharma-news","tag-nash","tag-pharma-news","industry-pharmaceutical","therapeutic_areas-gastroenterology","therapeutic_areas-oncology","therapeutic_areas-womens-health"],"acf":[],"yoast_head":"\nAZ announces positive results for durvalumab and tremelimumab<\/title>\n<meta name=\"description\" content=\"Gilead Sciences and Glympse Bio have announced a collaboration days after its JAK-inhibitor filgotinib stumbled in trials for Lupus and Sjogren's syndrome.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-az-allergan-gilead-glympse-bio\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AZ announces positive results for durvalumab and tremelimumab\" \/>\n<meta property=\"og:description\" content=\"Gilead Sciences and Glympse Bio have announced a collaboration days after its JAK-inhibitor filgotinib stumbled in trials for Lupus and Sjogren's syndrome.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-az-allergan-gilead-glympse-bio\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-10-29T06:53:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/10\/09022449\/News_29.10.2019.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AZ announces positive results for durvalumab and tremelimumab","description":"Gilead Sciences and Glympse Bio have announced a collaboration days after its JAK-inhibitor filgotinib stumbled in trials for Lupus and Sjogren's syndrome.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-az-allergan-gilead-glympse-bio","og_locale":"en_US","og_type":"article","og_title":"AZ announces positive results for durvalumab and tremelimumab","og_description":"Gilead Sciences and Glympse Bio have announced a collaboration days after its JAK-inhibitor filgotinib stumbled in trials for Lupus and Sjogren's syndrome.","og_url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-az-allergan-gilead-glympse-bio","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-10-29T06:53:19+00:00","article_modified_time":"2021-07-24T07:27:36+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/10\/09022449\/News_29.10.2019.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-az-allergan-gilead-glympse-bio","url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-az-allergan-gilead-glympse-bio","name":"AZ announces positive results for durvalumab and tremelimumab","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-az-allergan-gilead-glympse-bio#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-az-allergan-gilead-glympse-bio#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/10\/09022449\/News_29.10.2019.jpg","datePublished":"2019-10-29T06:53:19+00:00","dateModified":"2021-07-24T07:27:36+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Gilead Sciences and Glympse Bio have announced a collaboration days after its JAK-inhibitor filgotinib stumbled in trials for Lupus and Sjogren's syndrome.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-az-allergan-gilead-glympse-bio"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-az-allergan-gilead-glympse-bio#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/10\/09022449\/News_29.10.2019.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/10\/09022449\/News_29.10.2019.jpg","width":772,"height":482,"caption":"Pharma News"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/10\/09022449\/News_29.10.2019-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">delveinsight pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Gilead<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">NASH<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">delveinsight pharma news<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">Gilead<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">NASH<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Oct 29, 2019","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Oct 29, 2019 12:23 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"Pharma News","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/6279","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=6279"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/6279\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/6280"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=6279"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=6279"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=6279"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=6279"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=6279"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}